Overview: Why These Three?

Semaglutide (GLP-1R mono-agonist), Tirzepatide (GLP-1R/GIPR dual agonist), and Retatrutide (GLP-1R/GIPR/GCGR triple agonist) represent three successive generations of incretin-based research — each adding an additional receptor target and, according to clinical data, meaningfully greater efficacy. This comparison synthesises the Phase 2/3 trial data directly.

Mechanism Comparison

Phase 2/3 Efficacy Data

What the GCGR Component Adds

The key question in retatrutide research is: what does glucagon receptor agonism add on top of GLP-1R + GIPR? The clinical and preclinical data suggests three distinct contributions:

1. Direct hepatic fat mobilisation. GCGR activation in hepatocytes directly upregulates CPT1A and fatty acid oxidation — reducing liver fat (NAFLD/NASH) independently of caloric restriction. This is why retatrutide shows superior NASH data vs tirzepatide.

2. Brown adipose thermogenesis. GCGR activation in BAT increases uncoupling protein (UCP1) expression and non-shivering thermogenesis — raising basal metabolic rate independently of food intake. This energy expenditure component is absent in GLP-1 and GIP-only compounds.

3. Amplified lipolysis. GCGR triggers cAMP-mediated lipolysis in white adipose tissue — mobilising stored fat directly, not just reducing fat storage. The combination of reduced intake (GLP-1R), improved insulin sensitivity (GIPR), and direct fat mobilisation (GCGR) creates three independent fat-reduction signals simultaneously.

Frequently Asked Questions

Which compound produces the most weight loss?

Based on current clinical data: Retatrutide 12mg produced −24.2% at 48 weeks (Phase 2), Tirzepatide 15mg produced −20.9% at 72 weeks (Phase 3), Semaglutide 2.4mg produced −14.9% at 68 weeks (Phase 3). Retatrutide’s Phase 3 data is pending.

What does GIP receptor activation add to GLP-1R agonism?

GIPR activation in adipose tissue enhances insulin sensitivity in fat cells and may synergise with GLP-1R in the hypothalamus for appetite suppression. The GIPR contribution explains tirzepatide’s superior efficacy vs semaglutide at comparable GLP-1R occupancy.

What does glucagon receptor activation add?

GCGR activation adds three mechanisms absent from GLP-1/GIP: direct hepatic fat oxidation, BAT thermogenesis, and direct adipose lipolysis. These energy expenditure signals explain the step-change from ~21% (tirzepatide) to ~24% (retatrutide) weight reduction.

Are these compounds available for research?

Yes — QSC stocks research-grade Semaglutide, Tirzepatide, and Retatrutide at ≥99% HPLC purity with Janoshik COA verification. All available in multiple vial sizes for different research protocols.